Last reviewed · How we verify
Biotin-Labeled Red Blood Cells
At a glance
| Generic name | Biotin-Labeled Red Blood Cells |
|---|---|
| Sponsor | Gladwin, Mark, MD |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion (PHASE1)
- Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling (EARLY_PHASE1)
- Biotin-Acridine Red Cell Exchange Kinetics (PHASE2)
- Red Blood Cell Survival in Sickle Cell Disease (PHASE1)
- Optimization of Biotinylation Protocol for Studies of Red Blood Cell Survival and Function After Transfusion (EARLY_PHASE1)
- Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease (EARLY_PHASE1)
- Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c (NA)
- Transfusion of Biotinylated Red Blood Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biotin-Labeled Red Blood Cells CI brief — competitive landscape report
- Biotin-Labeled Red Blood Cells updates RSS · CI watch RSS
- Gladwin, Mark, MD portfolio CI